Menu

First Ever iPS-Cell Trial a Go

The Japanese government will allow a study of stem cell therapy using patients’ own cells, reprogrammed to be stem cells, to treat vision loss.

Jul 22, 2013
Bob Grant

WIKIMEDIA, SHELOVESGHOSTSResearchers in Japan will conduct a small clinical trial of a stem-cell treatment for age-related macular degeneration (AMD), which causes blindness in older people, after receiving the Japanese government’s permission last week to commence the study, according to Agence France-Presse (AFP). Scientists at the Riken Center for Developmental Biology and the Institute of Biomedical Research and Innovation Hospital will take adult skin cells from six AMD patients and reprogram them to into a stem-like state, before injecting them back into the subjects’ retinas to treat the disorder.

The trial, which will take place in Kobe, will be the first to test a treatment using such induced pluripotent stem cells (iPSCs) in humans, though ongoing trials in the U.S. are already testing the effectiveness of treating AMD patients with human embryonic stem cells (hESCs). A successful iPSC approach would allow patients to be treated with their own cells, however, avoiding rejection and the ethical issues that come along with hESC-therapies.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!